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Background:  Diabetics (DM) with coronary artery disease have higher platelet aggregation and activation compared to non-diabetics (NDM) 
despite treatment with similar aspirin (ASA) doses. Peripheral arterial disease (PAD) patients are known to have activated platelets and high 
prevalence of DM. We evaluated if DM further impairs platelet functions (PF) in PAD patients on ASA.
Methods:  PAD patients on 325 mg ASA and no other antiplatelet agent were included. Arachidonic acid (AA), collagen (CG), epinephrine (EP) and 
adenosine diphosphate (ADP) induced platelet aggregation was measured by optical aggregometry. EP and ADP closure time (CT) was measured 
with Platelet Function Analyzer (PFA)-100. Platelet activation was measured as mean fluorescence intensity (MFI) of CD62P. Shear induced platelet 
aggregation (SIPA) and shear induced P-selectin expression (SIPE) were measured.
Results:  Despite higher glycosylated hemoglobin (HBA1c), there was no difference in platelet function assays in DM and NDM PAD patients (Table). 
HBA1c did not correlate with aggregometry slope (AA, r: -0.01, p=0.9; CG, r: -0.04, p=0.6; ADP, r: 0.07, p=0.4; EP, r: 0.05, p=0.5), PFA-100 CT (EP, r: 
0.1, p=0.3; ADP, r: 0.07, p=0.9), SIPA % aggregation (r: 0.03; p=0.7) or MFI for CD62P (r: 0.05, p=0.6) and SIPE (r: 0.1, p=0.1).
Conclusions:  DM does not significantly affect PF assays in PAD patients on ASA. Whether in vivo platelet activation in PAD overrides the effect of 
DM on PF or high dose ASA offsets the same requires further evaluation.
Platelet functions in diabetic and nondiabetic PAD patients
Assay
(Median,25;75 IR)
Non-diabetics
(n=42)
Diabetics
(n=24)
p
HBA1c (%) 5.8 (5.7;6.2) 7.1 (6.5;8.3) <0.001
Aggregometry (Sl)
AA (0.5mg/mL)
CG (5 μg/mL)
ADP (10 μm/L)
EP (10 μm)
5.3 (0; 16.0)
20.0 (12.3;25.3)
33.5 (26.0;42.3)
13.5 (7.8;18.0)
6.5 (1.5;8.5)
25.0 (17.5;30.5)
33.0 (28;46.5)
13.5 (9.8;18.0)
0.9
0.8
0.6
0.9
PFA-100 (CT)
ADP (10 μm/L)
EP (10 μm)
86.0 (76.0;108.0)
289 (103;300)
95.0 (88.0;108.0)
300 (144;300)
0.2
0.5
SIPA (%)
5000 s-1
10000 s-1
41.7 (28.5;50.1)
83.2 (77.9;89.2)
48.4 (26.7;56.5)
85.5 (81.2;89.3)
0.5
0.4
P-selectin (MFI)
CD62P
SIPE 0 s-1
SIPE 5000 s-1
SIPE 10000 s-1
13.6 (11.1;19.3)
1.7 (1.0;3.4)
1.9 (1.4;4.7)
4.7 (3.7;6.8)
13.9 (10.3;19.1)
2.4 (1.3;2.7)
2.6 (1.7;4.2)
6.3 (3.1;7.9)
0.9
0.6
0.5
0.6
